GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (MIC:REGN-RM) » Definitions » Moat Score

Regeneron Pharmaceuticals (MIC:REGN-RM) Moat Score : 8/10 (As of Jul. 18, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Regeneron Pharmaceuticals Moat Score?

Regeneron Pharmaceuticals has the Moat Score of 8, which implies that the company might have Wide Moat - Clear and robust wide moat.

Regeneron Pharmaceuticals has Wide Moat: Regeneron Pharmaceuticals Inc possesses a robust wide moat due to its strong R&D capabilities, valuable patents, and significant market leadership in biotechnology, providing durable competitive advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Regeneron Pharmaceuticals might have Wide Moat - Clear and robust wide moat.

Competitive Comparison of Regeneron Pharmaceuticals's Moat Score

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regeneron Pharmaceuticals's Moat Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Moat Score falls into.


;
;

Regeneron Pharmaceuticals  (MIC:REGN-RM) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Regeneron Pharmaceuticals Moat Score Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Moat Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Regeneron Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (MIC:REGN-RM) » Definitions » Moat Score
Comparable Companies
ALNY ONC BNTX INSM SMMT RPRX INCY EXEL BMRN MRNA VRTX ASX:CSL XKRX:207940 XBRU:UCB XBRU:ARGX XKRX:068270 HKSE:01801 XKRX:196170 HKSE:02269 OCSE:GMAB
Traded in Other Exchanges
REGN:USA REGN:Mexico 1REGN:Italy 0R2M:UK RGO:Germany RGO:Germany REGN34:Brazil REGN:Austria
Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Website
https://www.regeneron.com
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals Headlines

No Headlines